Cargando…
Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/MAPK Pathway of Hepatic Stellate Cells
Liver fibrosis constitutes a significant health problem worldwide due to its rapidly increasing prevalence and the absence of specific and effective treatments. Growing evidence suggests that apoptosis-signal regulating kinase 1 (ASK1) is activated in oxidative stress, which causes hepatic inflammat...
Autores principales: | Yoon, Young-Chan, Fang, Zhenghuan, Lee, Ji Eun, Park, Jung Hee, Ryu, Ji-Kan, Jung, Kyung Hee, Hong, Soon-Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Applied Pharmacology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585640/ https://www.ncbi.nlm.nih.gov/pubmed/32451370 http://dx.doi.org/10.4062/biomolther.2020.016 |
Ejemplares similares
-
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
por: Loomba, Rohit, et al.
Publicado: (2017) -
HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
por: Son, Mi Kwon, et al.
Publicado: (2013) -
Clusterin Attenuates Hepatic Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Downregulating the Smad3 Signaling Pathway
por: Seo, Hye-Young, et al.
Publicado: (2019) -
Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1–JNK–DRP1 pathway
por: Lou, Guohua, et al.
Publicado: (2021) -
Selonsertib Alleviates the Progression of Rat Osteoarthritis: An in vitro and in vivo Study
por: Yan, Jiyuan, et al.
Publicado: (2021)